Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology

TSX:CXR.R - Post by User

Concordia Healthcare Corp. > BNN Coverage of New CEO

<< Previous

Bullboard Posts

Next >>

Comment by MustardTiger88on Nov 02, 2016 5:53pm

64 Views

Post# 25418261

RE:RE:RE:RE:RE:RE:RE:RE:BNN Coverage of New CEO

I believe on their website it states that no drug represents more than 10%. Unfortunately I think Donnatal is almost 10%.

Lumberfeverlong wrote: No drug representing more than 2% of revenue is simply not true. I think d
Donnatal, Plaquinel and Nilandron each represent more than that.

Nossy45 wrote: I don't think anyone thinks the institutional shorts will leave this alone anytime soon, doesn't mean there isn't upside from here though.

This solution to the is to issue a generic. Amco controls a monopoly over Liothryonine, I don't see the UK government being as draconian as people assume they will be.

Also important to note that CXR has access to a broad market, and no single drug represents more than 2% or so of revenues. So, these headwinds can be mitigated to a degree.

This entire issue is very complex, and is why the stock valuation of CXR has been knocked down so much.